Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

The global trial enrolled patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors had a ...

A cancer treatment from Roche failed to improve survival in a major lung cancer study, a result that will stoke doubts about ...

Susan Wojcicki, a non-smoker and CEO of YouTube, was diagnosed with non-small cell lung cancer in 2022 at the age of 56. She ...

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in a closely followed Phase 3 study called SKYSCRAPER-01.

Learn how a young woman diagnosed with stage 4 non-small cell lung cancer had many treatment options because she came to MSK first.

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Low-dose CT scans can help improve lung cancer survival rates with minimal radiation and no invasive procedures.

Genentech announced that the Phase III SKYSCRAPER-01 study, which evaluated tiragolumab combined with Tecentriq (atezolizumab) versus ...

Last November, Pyxis revealed it would continue to focus on PYX-201 as its lead asset, while pausing other early-stage ...